Non-invasive prenatal testing (NIPT) is a prenatal screening method that provide information about the risk of chromosome abnormalities by analysing placental DNA that is circulating in a pregnant woman’s blood.
Advances in adult stem cell research and their clinical application prompted interest in their use in assisted reproduction.
After losing a pregnancy, there are many unanswered questions. As humans, we may want answers because that helps us navigate the future with more certainty.
NIPT has increasingly become part of routine prenatal screening due to its many benefits.
Chromosomal aneuploidies are the most common cause of first-trimester miscarriage, accounting for approximately 50% of spontaneous abortions.
Newborn screening is a worldwide recognised public health measure aimed at the early screening, diagnosis and management of selected metabolic diseases.
Discover how pre-implantation genetic screening can reduce the risk of miscarriage and genetic conditions during IVF.
Exciting clinical work continues in transplant medicine and mesenchymal stem cell therapy. Recent studies from China highlight the co-transplantation of umbilical cord mesenchymal stem cells (UC-MSC) and umbilical cord blood haematopoietic stem cells (CB-HSC).
Next Biosciences’ role in developing FirstScreen with North-West University is to establish a newborn screening programme that is widely accessible to South African doctors and patients.
Act now to give your baby the best chance for a healthy future. Learn about newborn screening and how it can detect serious conditions early on.
